Royal Bank Of Canada Icosavax, Inc. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.95 - $15.79 $14,476 - $38,417	2,433 Added 40.04%	8,509 $134,000
Q3 2023 Nov 14, 2023	SELL	$7.22 - $10.05 $321,882 - $448,049	-44,582 Reduced 88.01%	6,076 $47,000
Q2 2023 Aug 14, 2023	BUY	$4.89 - $10.57 $241,585 - $522,200	49,404 Added 3939.71%	50,658 $503,000
Q1 2023 May 15, 2023	SELL	$5.62 - $11.51 $7,379 - $15,112	-1,313 Reduced 51.15%	1,254 $7,000
Q4 2022 Feb 14, 2023	BUY	$2.32 - $10.97 $5,326 - $25,187	2,296 Added 847.23%	2,567 $20,000

Q3 2022 Nov 14, 2022	BUY	$3.09 - $9.21 $451 - $1,344	146 Added 116.8%	271 $1,000
Q2 2022 Aug 15, 2022	SELL	$5.7 - $10.33 $7,757 - $14,059	-1,361 Reduced 91.59%	125 $1,000
Q1 2022 May 16, 2022	SELL	$4.41 - $22.5 $5,821 - $29,700	-1,320 Reduced 47.04%	1,486 $10,000
Q4 2021 Feb 14, 2022	BUY	$21.07 - $34.98 $27,664 - $45,928	1,313 Added 87.94%	2,806 $65,000
Q3 2021 Nov 15, 2021	BUY	$24.85 - $40.25 $37,101 - $60,093	1,493 New	1,493 $44,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.